A PDUFA date works as a sales trigger because it puts a public deadline on commercial spend. Once a drug developer has positive Phase 3 data, an NDA or BLA submission and an FDA goal date, it has to buy launch strategy, market access, medical affairs, commercial operations and field capacity against that date. Vendors who track the chain from topline reach the buyer while scope is open. Vendors who wait for the approval headline reach a team that already signed.
TL;DR: For a new molecular entity on standard review, the FDA goal date sits about 12 months after submission (a 60-day filing review plus a 10-month clock). Priority review cuts that to about 8 months. Many commercial vendor decisions happen between Phase 3 topline and the Day 74 letter, not at approval. FDA does not confirm pending applications, so every date comes from the company: press releases, 8-Ks, quarterly reports and earnings calls.
Why is a PDUFA date a sales trigger?
A PDUFA goal date is the day by which FDA aims to act on a marketing application, and it is the fixed point a pre-commercial company schedules its launch spend backwards from.
The owner of a consultancy that sells to pharma commercial teams told us the chain the firm watches: "once they get a phase three positive data readout ... we submitted an NDA, a BLA, we know we've a PDUFA coming up". Each step in that sentence is a separate public event with its own date, and each moves a different budget.
The trigger is also scarce. CDER approved 46 novel drugs in 2025. The list of companies approaching approval in any quarter is short enough to cover in full.
The regulator will not hand you that list. Under 21 CFR 314.430, FDA does not publicly disclose that an application exists before it sends an approval or tentative approval letter, unless the existence of the application has already been publicly disclosed or acknowledged. 21 CFR 601.51 sets the same rule for biologics license applications. Submission, acceptance and the goal date reach the public only when the applicant announces them.
Track buying signals across your accounts
Real-time alerts on leadership changes, earnings, hiring, and news — from 1,000+ sources.
What is the milestone chain from Phase 3 topline to launch?
The chain has six steps: Phase 3 topline, NDA or BLA submission, the Day 60 filing decision, the Day 74 letter, late-review meetings, and FDA action on the goal date. The first interval is set by the company. The rest are set by regulation and by the PDUFA VII commitment letter, which covers fiscal years 2023 through 2027.
| Step | What happens | Timing |
|---|---|---|
| Phase 3 topline | Company reports primary endpoint results | Company's own schedule after primary completion |
| Submission | NDA (drugs) or BLA (biologics) sent to FDA | Company's own schedule; often guided publicly as a quarter |
| Day 60 | FDA decides whether the application is sufficiently complete to file | Within 60 days of receipt |
| Day 74 letter | FDA sends filing review issues, the planned review timeline and preliminary advisory committee plans | Within 74 calendar days of receipt |
| Advisory committee, if held | Outside experts discuss the application in public | No later than 2 months (standard) or 6 weeks (priority) before the goal date |
| Late-cycle meeting, if no committee | FDA and applicant review open issues | No later than 3 months (standard) or 2 months (priority) before the goal date |
| Goal date | FDA approves or issues a complete response letter | See clocks below |
| Resubmission after a complete response | FDA reviews the amended application | 2 months (Class 1) or 6 months (Class 2) from receipt |
The Day 74, advisory committee and late-cycle timings are the commitments for new molecular entity NDAs and original BLAs. The review clocks differ by application type:
- New molecular entity NDAs and original BLAs. The goal is to act on 90 percent of standard applications within 10 months of the 60-day filing date, and priority applications within 6 months of the 60-day filing date. Counted from submission, that is roughly 12 months and 8 months.
- Other original NDAs (new formulations, new combinations and similar). The goal is 10 months from receipt for standard review and 6 months from receipt for priority review.
FDA tells the applicant whether it received priority review within 60 days of receipt. So by the time a company announces acceptance, it knows the goal date, the review class and whether a committee is planned.
“We had a variety of tools, and that was the pain — the variety. We had to go to multiple places to get streamlined data.”
Lyndsay Thomson
Head of Sales Operations, Cytel
Which vendors buy at which milestone?
Strategy and market access spend starts at Phase 3 topline. Infrastructure spend follows submission. Field spend follows acceptance. The table below is a planning framework built from the review clocks above plus one published hiring timeline. Adjust the lead times against your own closed deals.
| Milestone | Who starts buying | Lead time before a standard-review approval |
|---|---|---|
| Positive Phase 3 topline | Launch strategy, pricing and market access consulting, forecasting, executive search for commercial leadership | More than 12 months (before submission) |
| NDA or BLA submission | Medical affairs build, commercial operations (CRM, data, analytics), brand and marketing agencies, patient services design | About 12 months (about 8 on priority review) |
| Acceptance and goal date announced | Field force sizing and alignment, incentive compensation, contract sales, training, distribution and specialty pharmacy partners | About 10 months (about 6 on priority review) |
| Advisory committee or late-cycle stage | Sales management hiring, launch meeting production, speaker programmes, fulfilment | 2 to 3 months |
| Approval | Rep hiring completes, execution and post-launch analytics | Zero |
The hiring anchors come from a Pharmaceutical Executive timeline published in 2018: a shell commercial team (chief commercial officer, managed care, sales operations) about 18 months before the PDUFA date, medical science liaisons about 12 months out, front-line sales managers 4 to 6 months out, and reps just before or after launch. Eighteen months before the goal date is before submission. The first commercial hires and consulting engagements are triggered by the data, not the filing.
A BD leader at a mid-size CRO put the general rule in one line: "old data is old data ... follow the money, you follow the opportunities." In late-stage pharma the money moves at topline.
Where does each milestone show up publicly first?
Almost every milestone appears first in a company press release, and for US-listed companies that release usually reaches EDGAR attached to a Form 8-K.
| Milestone | First public source | How to monitor |
|---|---|---|
| Phase 3 primary completion | ClinicalTrials.gov record. Sponsors of covered trials must update the primary completion date within 30 calendar days of reaching it | Save the trial record and check the anticipated date monthly |
| Phase 3 topline | Press release, often furnished under 8-K Item 7.01 or filed under Item 8.01 | EDGAR alerts on the company; investor email alerts |
| Planned submission timing | Earnings call remarks, 10-Q and 10-K pipeline sections, corporate decks | Read the regulatory paragraph each quarter |
| Submission and acceptance | Press release and 8-K; the acceptance release usually carries the goal date | EDGAR full-text search for "PDUFA" and "New Drug Application" |
| Advisory committee | FDA advisory committee calendar and the Federal Register, which carries notice at least 15 days ahead | Check the calendar weekly for your accounts |
| Approval or complete response | Press release and 8-K; approvals also post to Drugs@FDA, which is updated daily | Same-day alert |
Two details save time.
The 8-K items are optional vehicles. Form 8-K lets a company use Item 7.01 for Regulation FD disclosure and Item 8.01 for any event it considers important to security holders. Neither is specific to clinical data, so filter on the attached press release, not the item number. Private companies file no 8-K. For them the press release, pipeline page and careers page are the whole record.
EDGAR is free to query. The SEC's data.sec.gov APIs return each filer's submission history as JSON, need no API key, and update with a typical delay of under a second. Full-text search covers more than 20 years of filings.
“Salesmotion is helping Cytel elevate our enterprise sales performance by embedding account intelligence directly into our workflow. The platform gives our commercial team real-time visibility into key account movements.”
Jonathan Burr
Chief Commercial Officer, Cytel
How do you tell a first-launch company from an established one?
A first-launch company is hiring its commercial leadership for the first time. An established company already has the functions and is staffing a brand team. The first buys infrastructure and advice from scratch. The second buys capacity through procurement and preferred-vendor lists.
Signs of a first launch:
- No marketed product in the 10-K
- A first chief commercial officer, or first heads of market access, commercial operations, trade and distribution, and medical affairs
- Job posts for roles that build systems, such as sales operations, CRM administration, incentive compensation and data management
An established launcher posts for a brand or launch lead inside an existing business unit and makes no new C-level commercial hire.
If the asset is partnered and the partner holds commercial rights in your territory, the buyer is the partner. The small company's press release is still your trigger. The contact list is not.
Related reading: pharma buying signals and the funding round as a sales trigger.
Worked example: one fictional launch, dated end to end
This example is illustrative. Marlowick Bio is a fictional company and the dates are invented to show the arithmetic.
Marlowick is a US-listed biotech with one late-stage new molecular entity and no marketed product.
- 9 September 2025. Positive Phase 3 topline. Press release attached to an 8-K. Management says it plans to submit an NDA in the first quarter of 2026. Trigger for launch strategy, pricing and market access work.
- October to November 2025. Careers page adds a VP of market access and a head of commercial operations. The 10-Q says the company has begun building commercial capabilities. A first launch, built from zero.
- 2 March 2026. NDA submitted and announced. Trigger for medical affairs, commercial systems and agency selection.
- 1 May 2026. Day 60. The application is filed.
- 15 May 2026. Day 74. The company announces acceptance with standard review and a goal date of 1 March 2027 (10 months from the 60-day filing date). No advisory committee is planned. Trigger for field force design, training and distribution partners.
- By 1 December 2026. Late-cycle meeting window (no later than 3 months before the goal date). Sales managers are being hired.
- 1 March 2027. Goal date.
With priority review, the goal date would have been 1 November 2026.
A launch consultancy that first wrote to Marlowick in September 2025 had about 18 months and an empty org chart to work with. One that wrote in March 2027 was congratulating a team with signed vendors.
How do you monitor this without building a tracker yourself?
Start with a fixed account list and four alert sources, and decide in advance which play each event triggers. The consultancy quoted above had built its tracking in-house on the EDGAR API and ClinicalTrials.gov, and described the result as clunky. The data is free. The upkeep is not.
A workable routine:
- Build the list from Phase 3. Pull industry-sponsored Phase 3 trials with primary completion in the next 12 months.
- Set alerts per company. EDGAR filings, press releases, the trial record and the careers page.
- Log four dates per asset. Topline, submission, acceptance, goal date. Compute the goal date yourself when a company gives only a submission date.
- Assign one play per date, by service line and buyer title, and review weekly.
Teams that do not want to maintain scripts can use an account monitoring platform. Salesmotion, for example, watches a named account list across news, SEC filings, hiring, funding and clinical trial activity, and attaches contacts to each account. The life sciences overview, the page for consultancies and recruiters and sales intelligence for pharma show how that maps to this workflow.
The discipline is the same as for any compelling event: a dated event, a named buyer and a reason to talk before the date. For the wider account approach, see selling to pharmaceutical companies.
Frequently Asked Questions
What is a PDUFA date?
A PDUFA date is the goal date by which FDA aims to act on an NDA or BLA under the Prescription Drug User Fee Act commitments. For new molecular entities and original BLAs, the goal is 10 months from the 60-day filing date on standard review and 6 months on priority review.
How long after an NDA submission is the PDUFA date?
For a new molecular entity on standard review, about 12 months: a 60-day filing review, then a 10-month clock. On priority review, about 8 months. For other original NDAs, the clock runs from receipt, so the goal date is 10 months (standard) or 6 months (priority) after submission.
Does FDA publish a list of upcoming PDUFA dates?
No. FDA does not publicly disclose the existence of a pending application before approval unless it has already been disclosed. Goal dates become public when the applicant announces them, usually in the press release that reports acceptance of the application.
Which 8-K items carry Phase 3 and FDA news?
US-listed companies usually attach the press release to an 8-K under Item 7.01 (Regulation FD Disclosure) or Item 8.01 (Other Events). Both are optional disclosure items and both are used for many other kinds of news. Search the exhibit text for terms such as topline, New Drug Application, Biologics License Application and PDUFA.
When should a vendor first contact a company approaching a PDUFA date?
Strategy, pricing and market access firms should make contact at positive Phase 3 topline. Medical affairs, commercial operations and agency vendors should be in conversation by submission. Field force, training and distribution vendors should be in conversation by the acceptance announcement. First contact at approval is late for nearly every category.
The companies that will launch next year are announcing their milestones this quarter. Watch the topline, not the approval.
